Avanos Medical (AVNS) investor relations material

Executive summary

• A merger agreement was entered into on April 13, 2026, under which the company will become a wholly-owned subsidiary of a parent entity, with a special shareholder meeting scheduled for July 22, 2026 to vote on the transaction.

• Supplemental proxy disclosures were issued in response to shareholder lawsuits and demand letters alleging disclosure deficiencies, though the company denies any wrongdoing.

• The board unanimously recommends voting in favor of the merger, advisory compensation, and adjournment proposals.

• Forward-looking statements highlight risks such as timing uncertainties, competing proposals, and potential impacts on relationships with stakeholders.

Voting matters and shareholder proposals

• Shareholders are asked to vote on the approval and adoption of the merger agreement, advisory compensation, and adjournment proposals at the special meeting.

• Lawsuits seek to enjoin the merger and request additional disclosures; supplemental information was provided to address these concerns.

Board of directors and corporate governance

• The board continues to unanimously recommend approval of the merger and related proposals.

• Directors and executive officers may be deemed participants in the proxy solicitation, with details on their interests disclosed in SEC filings.